Travere Therapeutics, Inc. (TVTX) Key Metrics
TVTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.61B
- Enterprise value
- $5.77B
- P/E (TTM)
- —
- Forward P/E
- 39.8
- PEG ratio
- —
- Price / sales
- 7.9 10-yr median 5.7
- Price / book
- 229.9 10-yr median 4.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.14
TVTX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTVTX valuation Price multiples at each fiscal year-end price.
Price / sales+17.9%
6.9
2025 · hover or tap a bar for each year
20162025
Price / book+27.6%
29.7
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+24.0 pts
−0.6%
2025 · hover or tap a bar for each year
20162025
TVTX returns How much profit the business earns on the capital it uses.
Return on equity+218.1 pts
−29.4%
2025 · hover or tap a bar for each year
20162025
Return on invested capital+350.4 pts
−47.1%
2025 · hover or tap a bar for each year
20162025
Return on assets+42.2 pts
−4.3%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+141.1 pts
−4.2%
2025 · hover or tap a bar for each year
20162025
Asset turnover+142.7%
0.82
2025 · hover or tap a bar for each year
20162025
TVTX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+86.1%
$5.50
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.29
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.23
2025 · hover or tap a bar for each year
20162025
Book value per share+71.9%
$1.29
2025 · hover or tap a bar for each year
20162025
Shares outstanding+13.1%
89.2M
2025 · hover or tap a bar for each year
20162025
TVTX financial health Debt, liquidity and how easily interest is covered.
Debt / equity−57.9%
2.86
2025 · hover or tap a bar for each year
20162025
Net debt−$24.9M
$5.9M
2025 · hover or tap a bar for each year
20162025
Current ratio+31.8%
2.74
2025 · hover or tap a bar for each year
20162025
Interest coverage
-5.8
2025 · hover or tap a bar for each year
20162025
Debt / assets−19.6%
0.54
2025 · hover or tap a bar for each year
20162025
TVTX efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+2 days
40 days
2025 · hover or tap a bar for each year
20162025
Days of inventory−155 days
213 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−684 days
853 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+531 days
-600 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−31.6 pts
11.9%
2025 · hover or tap a bar for each year
20162025
TVTX valuation history
Fiscal year-endToday10-year median
TVTX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TVTX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TVTX price vs earnings per share
Share price at year-endEPS (right axis)
TVTX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.41B | $1.37B | $667.7M | $1.34B | $1.86B | $1.30B | $601.2M | $915.0M | $816.9M | $724.8M |
| Enterprise value | $3.41B | $1.41B | $505.6M | $1.30B | $1.57B | $1.15B | $417.6M | $661.0M | $561.3M | $513.3M |
| Price / sales | 6.9 | 5.9 | 4.6 | 12.2 | 14.1 | 6.5 | 3.4 | 5.6 | 5.3 | 5.4 |
| Price / book | 29.7 | 23.3 | 3.3 | 31.3 | 6.1 | 6.1 | 2.7 | 2.9 | 2.8 | 2.4 |
| Price / operating cash flow | 90.2 | — | — | — | — | — | — | — | 110.3 | — |
| EV / sales | 7.0 | 6.0 | 3.5 | 11.9 | 11.9 | 5.8 | 2.4 | 4.0 | 3.6 | 3.8 |
| EV / EBITDA | 153.7 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −0.7% | −23.4% | −16.7% | −20.8% | −9.7% | −13.1% | −24.4% | −11.2% | −7.3% | −6.6% |
| Free cash flow yield | −0.6% | −24.6% | −48.2% | −16.0% | −2.1% | −12.5% | −12.3% | −4.9% | −0.8% | −1.9% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $38.21 | $17.42 | $8.99 | $21.03 | $31.04 | $27.25 | $14.20 | $22.63 | $21.07 | $18.93 |
| Per share | ||||||||||
| Revenue per share | $5.50 | $2.96 | $1.96 | $1.72 | $2.20 | $4.17 | $4.14 | $4.06 | $4.00 | $3.49 |
| Earnings per share | −$0.29 | −$4.08 | −$1.50 | −$4.37 | −$3.01 | −$3.56 | −$3.46 | −$2.54 | −$1.54 | −$1.25 |
| Operating cash flow per share | $0.42 | −$3.01 | −$3.77 | −$2.92 | −$0.25 | −$0.90 | −$1.37 | −$0.62 | $0.19 | −$0.04 |
| Free cash flow per share | −$0.23 | −$4.29 | −$4.33 | −$3.37 | −$0.65 | −$3.42 | −$1.74 | −$1.10 | −$0.17 | −$0.35 |
| Cash per share | $3.62 | $4.70 | $7.63 | $7.06 | $9.24 | $7.61 | $9.41 | $11.66 | $7.75 | $6.68 |
| Book value per share | $1.29 | $0.75 | $2.70 | $0.67 | $5.05 | $4.44 | $5.22 | $7.87 | $7.56 | $8.04 |
| Tangible book value per share | $0.02 | −$0.57 | $1.30 | −$0.85 | $2.57 | $1.20 | $1.49 | $3.23 | $2.77 | $3.26 |
| Capex per share | $0.65 | $1.28 | $0.56 | $0.44 | $0.40 | $2.52 | $0.37 | $0.49 | $0.36 | $0.31 |
| Debt per share | $3.68 | $5.09 | $5.45 | $6.39 | $4.38 | $4.54 | $5.07 | $5.38 | $1.16 | $1.16 |
| Shares outstanding | 89.2M | 78.9M | 74.3M | 63.8M | 59.8M | 47.5M | 42.3M | 40.4M | 38.8M | 38.3M |
| Change in shares outstanding | +13.1% | +6.2% | +16.5% | +6.6% | +25.9% | +12.3% | +4.7% | +4.3% | +1.3% | +1.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −29.4% | −247.4% | −91.4% | −161.5% | −70.2% | −78.4% | −54.3% | −33.6% | −19.9% | −15.8% |
| Return on invested capital (ROIC) | −47.1% | −397.5% | — | — | −411.7% | −270.6% | −154.9% | −124.2% | −63.5% | −43.7% |
| Return on assets (ROA) | −4.3% | −46.5% | −15.2% | −38.4% | −26.0% | −28.0% | −22.3% | −16.7% | −11.4% | −9.2% |
| Return on tangible assets | −5.2% | −65.6% | −16.3% | −48.4% | −28.7% | −37.4% | −32.8% | −19.7% | −17.9% | −14.0% |
| Free cash flow margin | −4.2% | −145.3% | −221.4% | −196.1% | −29.5% | −82.0% | −42.1% | −27.2% | −4.3% | −10.1% |
| Financial health | ||||||||||
| Total debt | $328.7M | $401.6M | $404.8M | $407.5M | $262.0M | $215.7M | $214.9M | $217.5M | $45.1M | $44.4M |
| Cash & short-term investments | $322.8M | $370.7M | $566.9M | $450.2M | $552.9M | $361.6M | $398.5M | $471.5M | $300.6M | $255.9M |
| Net debt | $5.9M | $30.9M | −$162.1M | −$42.8M | −$290.9M | −$145.9M | −$183.7M | −$254.0M | −$255.6M | −$211.5M |
| Debt / equity | 2.86 | 6.80 | 2.02 | 9.51 | 0.87 | 1.02 | 0.97 | 0.68 | 0.15 | 0.14 |
| Debt / assets | 0.54 | 0.68 | 0.51 | 0.61 | 0.34 | 0.36 | 0.36 | 0.31 | 0.09 | 0.08 |
| Net debt / EBITDA | 0.27 | — | — | — | — | — | — | — | — | — |
| Current ratio | 2.74 | 2.08 | 3.47 | 3.42 | 4.70 | 4.43 | 4.50 | 4.74 | 3.80 | 3.99 |
| Quick ratio | 2.70 | 2.04 | 3.41 | 3.39 | 4.64 | 4.35 | 4.43 | 4.68 | 3.74 | 3.96 |
| Interest coverage | -5.8 | -29.0 | -34.2 | -29.0 | -10.1 | -9.2 | -5.3 | -8.2 | -12.2 | -12.3 |
| Working capital | $277.7M | $216.0M | $438.9M | $344.3M | $458.7M | $317.7M | $333.6M | $391.1M | $240.1M | $249.1M |
| Invested capital | $120.8M | $90.0M | $38.7M | $94,000 | $11.2M | $65.3M | $37.5M | $64.3M | $37.6M | $96.3M |
| Tangible asset value | $1.7M | −$44.9M | $96.4M | −$54.3M | $153.7M | $57.1M | $63.1M | $130.6M | $107.4M | $124.8M |
| Net current asset value | −$52.8M | −$118.3M | $28.7M | −$143.3M | $108.3M | $14.2M | $45.5M | $104.8M | $98.6M | $114.8M |
| Graham net-net per share | −$1.17 | −$1.79 | −$0.01 | −$2.58 | $1.57 | −$0.13 | $0.74 | $2.33 | $2.23 | $2.32 |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | — | — | — | — |
| Capex / revenue | 11.9% | 43.4% | 28.6% | 25.9% | 18.3% | 60.4% | 8.9% | 12.0% | 9.0% | 8.9% |
| Capex / operating cash flow | 153.9% | — | — | — | — | — | — | — | 189.2% | — |
| Capex / depreciation | 0.96 | 2.32 | 1.08 | 1.37 | 1.89 | 4.88 | 0.76 | 1.06 | 0.79 | 0.74 |
| Stock-based compensation / revenue | 9.1% | 15.8% | 30.5% | 34.8% | 22.4% | 11.9% | 12.0% | 12.0% | 17.3% | 21.8% |
| R&D / revenue | 42.0% | 121.2% | 168.7% | 207.7% | 152.6% | 66.4% | 80.4% | 75.3% | 50.5% | 53.0% |
| SG&A / revenue | 68.7% | 113.3% | 182.8% | 180.4% | 95.8% | 68.5% | 73.5% | 63.1% | 67.1% | 73.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 39.9 | 37.8 | 47.5 | 54.3 | 67.8 | 47.0 | 33.9 | 31.5 | 93.3 | 170.3 |
| Days of inventory on hand | 213.1 | 367.9 | 222.1 | 488.7 | 713.2 | 407.8 | 408.0 | 362.2 | 414.0 | 214.9 |
| Days payables outstanding | 853.2 | 1,536.8 | 939.8 | 1,339.2 | 1,303.8 | 1,154.3 | 1,170.5 | 854.9 | 1,339.5 | 607.6 |
| Cash conversion cycle (days) | -600.1 | -1,131.1 | -670.2 | -796.2 | -522.8 | -699.4 | -728.6 | -461.2 | -832.2 | -222.4 |
| Receivables turnover | 9.15 | 9.66 | 7.68 | 6.72 | 5.38 | 7.76 | 10.78 | 11.58 | 3.91 | 2.14 |
| Payables turnover | 0.43 | 0.24 | 0.39 | 0.27 | 0.28 | 0.32 | 0.31 | 0.43 | 0.27 | 0.60 |
| Inventory turnover | 1.71 | 0.99 | 1.64 | 0.75 | 0.51 | 0.89 | 0.89 | 1.01 | 0.88 | 1.70 |
| Asset turnover | 0.82 | 0.34 | 0.20 | 0.15 | 0.19 | 0.33 | 0.27 | 0.27 | 0.30 | 0.26 |
| Average receivables | $53.6M | $24.1M | $18.9M | $16.3M | $24.5M | $25.6M | $16.3M | $14.2M | $39.6M | $62.3M |
| Average payables | $24.2M | $32.6M | $29.5M | $16.2M | $13.6M | $19.4M | $16.8M | $12.9M | $13.2M | $7.6M |
| Average inventory | $6.0M | $7.8M | $7.0M | $5.9M | $7.5M | $6.8M | $5.9M | $5.5M | $4.1M | $2.7M |
| Intangibles / total assets | 18.7% | 17.5% | 13.2% | 14.4% | 19.1% | 25.4% | 26.1% | 26.5% | 35.7% | 34.8% |
Computed from TVTX's annual financial statements (latest annual report filed February 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TVTX valuation and financial ratios
Travere Therapeutics earned a return on equity of −29.4% and a return on invested capital of −47.1% in fiscal 2025. It ended the year with $328.7 million of debt and $322.8 million in cash and short-term investments, net debt of $5.9 million. The share count rose 133.0% from 38.3M to 89.2M over 9 years.
See the TVTX income statement, the TVTX chart for price history, or the TVTX stock overview for the latest quote and news.
TVTX key metrics FAQ
What is Travere Therapeutics's EV/EBITDA?
Travere Therapeutics's enterprise value was 153.7 times EBITDA at the end of fiscal 2025 (enterprise value $3.4 billion, EBITDA $22.2 million).
What is Travere Therapeutics's return on equity?
Travere Therapeutics's return on equity (ROE) was −29.4% in fiscal 2025: net income of -$25.5 million on average shareholders' equity of $87.0 million.
What is Travere Therapeutics's ROIC?
Travere Therapeutics's return on invested capital was −47.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Travere Therapeutics have?
Travere Therapeutics had total debt of $328.7 million at the end of fiscal 2025, a debt-to-equity ratio of 2.86 and $5.9 million of net debt (0.27 times EBITDA).
What is Travere Therapeutics's free cash flow yield?
Travere Therapeutics generated -$20.4 million of free cash flow in fiscal 2025, a free cash flow yield of −0.6% on its market value at year-end ($3.4 billion).
What is Travere Therapeutics's current ratio?
Travere Therapeutics's current ratio was 2.74 at the end of fiscal 2025: current assets were 2.74 times current liabilities.